miR‑132 inhibits high glucose‑induced vascular smooth muscle cell proliferation and migration by targeting E2F5

  • Authors:
    • Qun Xu
    • Ying Liang
    • Xiangjuan Liu
    • Chunmei Zhang
    • Xiaoqian Liu
    • Hong Li
    • Jiangjiu Liang
    • Guang Yang
    • Zhiming Ge
  • View Affiliations

  • Published online on: June 12, 2019     https://doi.org/10.3892/mmr.2019.10380
  • Pages: 2012-2020
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The dysregulated behavior of vascular smooth muscle cells (VSMCs) serves an important role in the pathogenesis of cardiovascular diseases in diabetes. The present study aimed to investigate the effects of microRNA (miR)‑132 on the proliferation and migration of VSMCs under high glucose conditions to mimic diabetes. We observed that the expression of miR‑132 was significantly decreased and that of E2F transcription factor 5 (E2F5) was upregulated in high glucose (HG)‑treated VSMCs or those obtained from diabetic rats. A dual luciferase reporter gene assay revealed that miR‑132 could specifically bind to the 3'‑untranslated region of E2F5 and significantly suppress the luciferase activity. The proliferation and migration of diabetic rat or HG‑treated VSMCs were increased compared with non‑diabetic rat VSMCs and those under normal glucose conditions. Upregulation of miR‑132 significantly inhibited the proliferation and migration of diabetic rat VSMCs; similar effects were observed following E2F5 downregulation. The inhibitory effects of miR‑132 on the proliferation and migration of HG‑treated VSMCs could be reversed by E2F5 overexpression. In conclusion, miR‑132 was proposed to inhibit the proliferation and migration of diabetic rat or high‑glucose‑treated VSMCs by targeting E2F5. The findings of the present study suggested that increasing the expression of miR‑132 may serve as a novel therapeutic approach to inhibit the progression of cardiovascular disease in diabetes.
View Figures
View References

Related Articles

Journal Cover

August-2019
Volume 20 Issue 2

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Xu Q, Liang Y, Liu X, Zhang C, Liu X, Li H, Liang J, Yang G and Ge Z: miR‑132 inhibits high glucose‑induced vascular smooth muscle cell proliferation and migration by targeting E2F5. Mol Med Rep 20: 2012-2020, 2019
APA
Xu, Q., Liang, Y., Liu, X., Zhang, C., Liu, X., Li, H. ... Ge, Z. (2019). miR‑132 inhibits high glucose‑induced vascular smooth muscle cell proliferation and migration by targeting E2F5. Molecular Medicine Reports, 20, 2012-2020. https://doi.org/10.3892/mmr.2019.10380
MLA
Xu, Q., Liang, Y., Liu, X., Zhang, C., Liu, X., Li, H., Liang, J., Yang, G., Ge, Z."miR‑132 inhibits high glucose‑induced vascular smooth muscle cell proliferation and migration by targeting E2F5". Molecular Medicine Reports 20.2 (2019): 2012-2020.
Chicago
Xu, Q., Liang, Y., Liu, X., Zhang, C., Liu, X., Li, H., Liang, J., Yang, G., Ge, Z."miR‑132 inhibits high glucose‑induced vascular smooth muscle cell proliferation and migration by targeting E2F5". Molecular Medicine Reports 20, no. 2 (2019): 2012-2020. https://doi.org/10.3892/mmr.2019.10380